High-dose carboplatin-irinotecan-temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma.

MLA

Kobushi, Hirokazu, et al. “High-Dose Carboplatin-Irinotecan-Temozolomide Is an Effective Salvage Chemotherapy for Relapsed or Refractory Neuroblastoma.” Pediatric Blood & Cancer, vol. 70, no. 7, July 2023, p. e30331. EBSCOhost, https://doi.org/10.1002/pbc.30331.

APA

Kobushi, H., Saida, S., Umeda, K., Iwai, A., Kozuki, K., Kubota, H., Tanaka, K., Obu, S., Uchihara, Y., Tasaka, K., Kato, I., Hiramatsu, H., & Takita, J. (2023). High-dose carboplatin-irinotecan-temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma. Pediatric Blood & Cancer, 70(7), e30331. https://doi.org/10.1002/pbc.30331

Chicago

Kobushi, Hirokazu, Satoshi Saida, Katsutsugu Umeda, Atsushi Iwai, Kagehiro Kozuki, Hirohito Kubota, Kuniaki Tanaka, et al. 2023. “High-Dose Carboplatin-Irinotecan-Temozolomide Is an Effective Salvage Chemotherapy for Relapsed or Refractory Neuroblastoma.” Pediatric Blood & Cancer 70 (7): e30331. doi:10.1002/pbc.30331.